查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球腫瘤影像人工智慧策略趨勢（2025-2032）—路徑、基礎技術與實用指南
市場調查報告書
商品編碼
1891236

全球腫瘤影像人工智慧策略趨勢（2025-2032）—路徑、基礎技術與實用指南

Global Oncology Imaging AI Strategy Pulse 2025-2032: Pathways, Platforms and Playbooks
出版日期: | 出版商: Marketstrat, Inc. | 英文 102 Pages | 訂單完成後即時交付

價格

摘要

預計全球癌症診斷領域的醫學影像人工智慧市場規模將從2023年的6.047億美元成長到2032年的77.4億美元，複合年增長率（CAGR）為32.7%。 這將成為影像人工智慧領域成長最快的市場之一。

"全球腫瘤影像人工智慧策略趨勢（2025-2032）—路徑、基礎技術和實用指南" 是Marketstrat發布的一份全球深度分析報告，揭示了醫療系統、原始設備製造商（OEM）和製藥公司如何採購、實施和擴展癌症影像人工智慧。

本報告將腫瘤學定位為醫學影像人工智慧的標竿應用案例。企業買家在此領域制定預算、治理規則、平台選擇和證據標準，這將對所有其他人工智慧成像領域產生連鎖反應。

本報告基於 Marketstrat 的 Markintel™ 框架，整合了以下內容：

  • 2023 年至 2032 年全球腫瘤影像人工智慧市場預測
  • 六大供應商集群的競爭格局（人工智慧軟體、原始設備製造商、放射腫瘤學、平台、供應商/遠端放射學以及診斷影像製藥/合約研究組織）
  • 利用專有矩陣（M3、ARC、GTM 成長-成熟度、升級和包裝階梯）的實用上市 (GTM) 和包裝策略手冊

本報告提供策略層面的視角，旨在為影像人工智慧、腫瘤 IT、放射學、放射治療、製藥、私募股權和醫療系統領域的管理人員提供超越總資產管理 (TAM) 數據的更深入分析。本報告將為貴組織提供策略基礎，幫助其確定在腫瘤影像人工智慧領域（截至 2032 年）的進入方向、建立競爭優勢以及產品包裝策略。

主要市場趨勢

1. 從單一功能電腦輔助診斷 (CAD) 到以測量為中心、以路徑為導向的人工智慧

  • 支出​​正從獨立的檢測應用轉向以測量為中心的工作流程，例如分割、體積測量、RECIST/PERCIST 工具、放射組學、PET 劑量測定和結構化報告。
  • 雖然檢測和診斷仍然是基礎，但隨著腫瘤委員會和支付方要求可重複的指標，而不僅僅是“人工智慧標記”，量化和分析以及報告和溝通變得越來越重要。

2.篩檢項目作為永續人工智慧預算的基礎

  • 美國、歐洲、中國、日本以及一些中等收入國家的國家和地區乳房數位乳房影像 (DBT) 和低劑量 CT (LDCT) 肺癌篩檢計畫已將人工智慧 (AI) 整合到其營運模式中（分流、二次閱片、品質保證、集中閱片）。
  • 供應商正日益將腫瘤人工智慧定位為篩檢和放射治療項目預算中的獨立項目，而不是實驗性的 IT 支出。

3. 治療診斷與放射治療計劃作為高價值細分市場

  • PSMA/SSTR 治療診斷 和先進的 PET/CT，結合自動勾勒和自適應放射治療，將創造對多時相定量人工智慧的需求。
  • 腫瘤影像人工智慧將成為驅動治療計劃、療效追蹤以及最終基於價值的腫瘤學模型的測量引擎。

4. 平台化、市場與治理

  • 與PACS整合的AI市場、中立的AI平台和雲端編排器消除了採用障礙，並支援在單一合約下使用多供應商的腫瘤解決方案。
  • 證據、驗證和監控能力（AIops）正成為明確的招標標準，而不僅僅是 "錦上添花" 。

5. 亞太地區的強勁動能與全球差距

  • 亞太地區的成長速度目前已超越歐洲，這主要得益於政府主導的篩檢和本土OEM廠商/平台的發展。
  • 與此同時，儘管拉丁美洲 (LATAM) 和中東及非洲 (MEA) 地區的普及程度仍然不均衡，但雲端優先、以患者為中心的定價模式以及遠距放射學模式的採用正在幫助縮小醫療服務獲取差距。

6. 監理速度作為競爭優勢

  • 在腫瘤領域，那些能夠穩定獲得 FDA、CE/MDR 和區域性批准的供應商正在贏得更多的商業競標和由支付方主導的試點計畫。
  • Marketstrat 的 ARC 指數（批准、報銷、臨床驗證）依用例和集群量化了這一差距。

競爭格局

本報告將腫瘤影像人工智慧的競爭格局劃分為六個清晰定義的集群，並分析每個集群的經濟性、底層技術和市場進入策略：

人工智慧軟體供應商

  • 乳房數位乳房斷層合成（DBT）、肺部CT、PET反應分析、放射組學和腫瘤委員會報告。
  • 主要驅動因素：乳房DBT套件、肺部CT分流與管理。

影像設備製造商（CT/MR/PET/DBT/US）

  • 腫瘤套裝的工廠配套和改裝配件（DBT+AI、肺部CT、PET定量、重建/劑量AI、PCCT腫瘤）。
  • 控制硬體安裝率和掃描器級捆綁銷售。

放射治療與腫瘤治療計畫供應商

  • 自動勾勒輪廓、計畫品質保證、自適應放射治療、反應關聯計畫和劑量累積。
  • 與治療計畫系統/​​直線加速器深度集成，在治療室層面創造價值。

人工智慧平台和雲端供應商

  • 中立的市場、編排層和受監管的人工智慧營運平台，支援透過單一合約進行部署和監控。

醫療機構與遠距放射學網絡

  • 人工智慧輔助篩檢、腫瘤診斷判讀、腫瘤委員會支持和網路品質保證。將應用層面的價值轉化為服務線收入和成果。

影像製藥/CRO/臨床試驗專業人員

  • 放射組學和定量終點、治療診斷定量、病灶水平反應分析、真實世界數據 (RWE) 和健康技術評估 (HTA) 支持。

本報告在每個集群中提供：

  • Markintel M3（市場動量矩陣）-將細分市場分成四個像限。
  • GTM 成長成熟度矩陣 -依集群可視化公司市場地位。
  • 競賽資料集與記分板 -供應商角色、通路、證據基礎與地理優勢。

這使策略制定者能夠清楚地了解在哪些方面應該尋求合作、競爭、收購或內部開發。

本報告的意義

1. 專為策略制定而生，而非僅是市場規模估算

許多人工智慧市場報告都以 "總市場規模 (TAM)" 的問題結尾。本報告旨在為腫瘤影像人工智慧領域的董事會、高階主管和業務部門決策提供支援。將價值直接與以下內容連結：

  • 產品組合選擇（優先模式、腫瘤部位和治療路徑階段）
  • 平台和合作策略（OEM、放射治療、平台、供應商、製藥）
  • 與證據和準備情況相符的定價、包裝和升級結構

2.明確注意治療路徑與應用率

腫瘤人工智慧影像的成長並非由掃描儀數量的增加所驅動，而是由應用率的提高和臨床流程的採用（篩檢、放射治療、診療一體化和治療反應監測）所驅動。該模型透過以下要素清晰地重建了收入：

  • 依模式和國家劃分的安裝基數和檢查量
  • 癌症人工智慧模組的工廠安裝率和改造安裝率
  • 依收入來源和最終用途劃分的平均售價/每位用戶平均收入區間

這使得預測對依賴應用率計算的原始設備製造商 (OEM)、軟體供應商和平台更有用，而不僅僅是首席資訊長 (CIO) 的儀錶板。

3.市場進入策略 (GTM) 和產品包裝的實用架構

Markintel 的框架堆疊將資料轉換為具體、可驗證的策略：

  • M3 市場動能矩陣
  • ARC 指數 清楚辨識已準備部署和處於試點階段的用例。
  • GTM 成長成熟度 矩陣以集群識別合作夥伴、併購目標和競爭對手。
  • 升級和包裝階梯 展示如何將腫瘤人工智慧打包成基礎型、高級型和精英型產品，並內建商業規則。

這尤其適用於：

  • 產品和組合負責人 - 決定投資、退出和打包哪些產品。
  • 市場推廣、商業和定價團隊 - 定義 SKU、底價和折扣結構。
  • 投資者和業務拓展/併購專業人士 - 識別具有結構性成長動能的平台和集群。

4. 基於證據的分析與供應商中立性

此分析以證據為依據，不帶任何炒作，涵蓋各地區的成熟企業和新興企業。它提供：

  • 對各集群中的領先供應商現有和新興供應商進行中立、系統化的分析。
  • 清晰展示排名和 ARC 評分的 "證據置信度" 。
  • 研究方法可根據新資料、試驗和審批的出現進行完善和擴展。

5. 可重複使用

表格、圖表和框架旨在以最小的修改直接整合到內部文件、投資委員會和業務發展備忘錄以及董事會材料中，從而幫助團隊：

  • 向非技術利害關係人解釋複雜的腫瘤人工智慧趨勢。
  • 基於量化、細分的證據來論證預算和策略投資的合理性。
  • 使產品、銷售和合作夥伴關係路線圖與對市場的共同理解保持一致。

公司列表：

  • 5C Network
  • Accuray
  • Aidoc
  • AIQ Solutions
  • Bracco
  • Brainlab
  • Canon Medical
  • CARPL.ai
  • deepc (deepcOS)
  • DocPanel
  • Elekta
  • Everlight Radiology
  • Ferrum Health
  • Fujifilm Healthcare
  • GE Health Care
  • Guerbet
  • Hologic
  • Incepto
  • Koios Medical
  • Lantheus/EXINI (aPROMISE/PYLARIFY AI)
  • Limbus AI
  • Lunit
  • Median Technologies
  • MIM Software
  • Mirada Medical
  • MVision AI
  • Nuance Precision Imaging Network (PIN)
  • Philips Healthcare
  • Quib​​im
  • QView Medical
  • RadNet/DeepHealth
  • RaySearch Laboratories
  • Riverain Technologies
  • Samsung Healthcare
  • ScreenPoint Medical (Transpara)
  • Siemens Healthineers
  • Teleradiology Solutions
  • Tempus (Arterys)
  • Therapixel （MammoScreen）
  • Unilabs/遠距醫療診所 (TMC)
  • 聯影醫療
  • Vara
  • vRad

這份名單均衡涵蓋了人工智慧軟體專家、影像設備原始設備製造商 (OEM)、放射治療設備/治療計畫系統供應商、平台營運商、醫療機構/遠距放射學網路以及專注於腫瘤分析的影像相關製藥公司/獨立合約研究組織 (iCRO)。

目錄

第一部分 - 如何利用此策略趨勢

  • 本次報告解答的問題
  • 此策略趨勢與地平線研究計畫的關聯
  • 哪些人應該使用本次報告以及原因？
  • 本文檔未涵蓋的內容
  • 如何閱讀文件其餘部分

第二部分 - 摘要整理

  • 為何此市場至關重要 - 25 秒速覽
  • 全球經濟成長概況 (2023-2032)
  • 資金流向何方？
  • 全球市場驅動因素與限制因素
  • 區域脈搏 - 誰會引領，誰會加速？
    • 北美
    • 亞太地區
    • 歐洲
    • 拉丁美洲、中東和非洲
  • 重要證據與政策訊號（2025-2027）
  • 五大戰略要點
  • 依模式、應用、途徑和最終用途劃分的結構性變化
  • 競爭架構與供應商集群
  • 三年關鍵績效指標展望（2025-2027）與董事會層級行動
    • 三年關鍵績效指標展望
    • 未來12個月的供應商舉措

第三部分 - 研究方法

第四部分 - 策略分析與架構

  • 跨集群策略手冊（2025-2027）
  • 人工智慧軟體集群
    • 摘要整理
    • Markintel M3 - 市場動能矩陣（主要人工智慧軟體細分市場）
    • Markintel ARC 框架 - 以人工智慧軟體視角解決腫瘤應用案例
    • Markintel ARC 網格 - 人工智慧軟體（腫瘤影像人工智慧）
    • Markintel GTM 成長成熟度矩陣 - 人工智慧軟體供應商（腫瘤影像人工智慧）
    • Markintel 升級與軟體套件階梯 - 人工智慧軟體（腫瘤影像人工智慧）
    • 公司聚焦 - 人工智慧軟體集群
      • Aidoc
      • AIQ Solutions
      • Koios Medical
      • Lunit
      • Median Technologies
      • Quib​​im
      • QView Medical
      • RadNet/DeepHealth
      • Riverain技術
      • ScreenPoint Medical (Transpara)
      • Therapixel (MammoScreen)
      • Vara
    • 影像OEM群聚（腫瘤附屬器及AI套件）
      • 摘要整理
      • Markintel M3 - 市場動能矩陣（主要影像OEM細分市場）
      • Markintel ARC框架 - OEM廠商解決的腫瘤影像AI用例
      • Markintel GTM成長成熟度矩陣 - 影像OEM（腫瘤影像AI）
      • 升級與封裝階梯 - 影像OEM鏡頭（腫瘤影像AI）
      • 尋找參與者 - 影像OEM（腫瘤附件及AI套件）
        • 佳能醫療
        • 富士軟片醫療
        • GE醫療
        • Hologic
        • 飛利浦醫療保健
        • 三星醫療
        • 西門子醫療
        • 聯影醫療
    • 放射治療/腫瘤規劃群聚（自動勾勒、自適應、劑量/反應）
      • 摘要整理
      • Markintel M3 - 關鍵細分市場市場動能矩陣（放射治療/腫瘤規劃視角）
      • Markintel ARC框架腫瘤應用案例（放射治療/腫瘤規劃視角）
      • Markintel GTM成長成熟度矩陣 - 放射治療與腫瘤規劃供應商（腫瘤影像AI）
      • Markintel升級與產品階梯 - 放射治療/腫瘤規劃
      • 公司聚焦 - 放射治療/腫瘤規劃
        • Accuray
        • Brainlab
        • Elekta
        • Limbus AI
        • MIM軟體
        • Mirada Medical
        • MVision AI
        • RaySearch Laboratories
        • Varian (Siemens)
    • AI 平台與雲端集群（中立平台、編排、市場）
      • 摘要整理
      • Markintel M3 - 市場動能矩陣（AI 平台和雲端的主要細分市場）
      • Markintel ARC 框架 - AI 平台和雲端解決的腫瘤應用案例
      • 升級和軟體包階梯 - AI 平台和雲端（腫瘤）
      • 公司聚焦 - AI 平台和雲
        • CARPL.ai
        • deepc (deepcOS)
        • Ferrum Health
        • Incepto
        • Nuance 精準成像網路 (PIN)
        • Tempus （動脈）
    • 醫療服務提供者和遠距放射學集群（人工智慧輔助服務）
      • 摘要整理
      • Markintel M3 市場動能矩陣（醫療服務提供者和遠距放射學的關鍵細分市場）
      • Markintel ARC 框架 - 醫療服務提供者和遠距放射學可觸及的腫瘤應用案例
      • 上市成長成熟度矩陣 - 醫療服務提供者和遠距放射學網路（腫瘤影像人工智慧）
      • Markintel 升級和套餐階梯 - 醫療服務提供者和遠距放射學（腫瘤）
      • 特色公司 - 醫療服務提供者和遠距放射學（人工智慧輔助服務）
        • 5C Network
        • Everlight Radiology
        • DocPanel
        • RadNet/DeepHealth
        • 遠距放射學解決方案
        • Unilabs/遠距醫療診所(TMC)
        • vRad
    • 影像製藥/CRO 和臨床試驗集群（放射組學、反應、診療一體化）
      • 摘要整理
      • Markintel M3 市場動能矩陣（影像 - 製藥/CRO 和臨床試驗的關鍵細分領域）
      • Markintel ARC 框架所涵蓋的腫瘤影像 AI 應用案例 - 影像 - 製藥/CRO 和臨床試驗
      • Markintel GTM 成長成熟度矩陣 - 影像製藥和 CRO（腫瘤影像 AI）
      • 升級和打包階梯 - 影像製藥/CRO 和臨床試驗
      • 特色公司 - 影像製藥/CRO 和臨床試驗（放射組學、反應、治療診斷）
        • AIQ 解決方案
        • 布拉科
        • 格伯特
        • Lantheus/EXINI（aPROMISE/PYLARIFY AI）
        • 中位數技術 〈li>奎賓
Product Code: MINTP-M01119-1

Summary

The global oncology segment of medical imaging AI grows from US$ 604.7M in 2023 to US$ 7.74B in 2032, a 32.7% CAGR, making it one of the fastest-expanding pools in imaging AI.

"Oncology Imaging AI Strategy Pulse 2025-2032: Pathways, Platforms & Playbooks" is Marketstrat's global deep-dive on how cancer imaging AI is actually being bought, deployed, and scaled across health systems, OEMs, and pharma.

The report positions oncology as the reference use case for medical imaging AI-where enterprise buyers are defining budgets, governance rules, platform choices, and evidence standards that will spill over into every other AI-imaging domain.

Built on Marketstrat's Markintel(TM) framework stack, the report combines:

  • A 2023-2032 global market forecast for oncology imaging AI
  • Competitive architecture across six vendor clusters (AI software, OEMs, RT, platforms, providers/telerad, imaging pharma/CRO)
  • Actionable GTM and packaging playbooks using proprietary matrices (M3, ARC, GTM Growth-Maturity, Upgrade & Package Ladders)

The result is a strategy-grade view designed for executives in imaging AI, oncology IT, radiology, RT, pharma, private equity, and health systems who need more than high-level TAM numbers. If your organization is deciding where to play, how to win, and how to package in oncology imaging AI between now and 2032, this report is designed to be the strategic baseline you build on.

Key Market Trends

1. From single-use CAD to pathway-centric, measurement-first AI

  • Spend is shifting from isolated detection apps to measurement-centric workflows: segmentation, volumetrics, RECIST/PERCIST tools, radiomics, PET dosimetry, and structured reporting.
  • Detection & diagnosis remains foundational, but Quantification & Analytics and Reporting & Communication gain share as tumor boards and payers demand reproducible metrics, not just "AI flags."

2. Screening programs as durable AI budget anchors

  • National and regional breast DBT and LDCT lung screening initiatives in the US, Europe, China, Japan, and selected middle income markets are embedding AI into operating models (triage, second reads, QA, centralized reading).
  • For vendors, oncology AI increasingly shows up as a line item in screening and RT program budgets, rather than experimental IT spend.

3. Theranostics & RT planning as high-value niches

  • PSMA/SSTR theranostics and advanced PET/CT, combined with auto-contour and adaptive RT, create demand for multi timepoint quantitative AI.
  • Oncology imaging AI becomes the measurement engine behind treatment planning, response tracking, and eventual value based oncology models.

4. Platformization, marketplaces, and governance

  • PACS-integrated AI marketplaces, neutral AI platforms, and cloud orchestrators remove deployment friction and enable multi-vendor oncology suites under a single contract.
  • Evidence, validation, and monitoring capabilities (AIops) are becoming explicit RFP criteria, not a nice to have.

5. APAC momentum and global equity gaps

  • APAC's growth rate now exceeds Europe's, driven by state-backed screening and domestic OEMs/platforms.
  • At the same time, adoption remains uneven in LATAM and MEA, where cloud-first, PPU and teleradiology models are emerging to bridge access gaps.

6. Regulatory velocity as a competitive moat

  • Vendors with a steady cadence of oncology-relevant FDA, CE/MDR, and local approvals are winning more enterprise tenders and payer pilots.
  • Marketstrat's ARC-Index (Approvals, Reimbursement, Clinical validation) quantifies this gap by use case and cluster.

Competitive Landscape

The report maps the oncology imaging AI landscape into six tightly defined clusters, each with its own economics, rails, and GTM logic:

AI Software Vendors

  • Breast DBT, CT-lung, PET response analytics, radiomics, tumor-board reporting.
  • Prime Drivers: breast DBT suites, CT-lung triage & management.

Imaging OEMs (CT/MR/PET/DBT/US)

  • Factory and retrofit attach on oncology packs (DBT+AI, CT-lung, PET quant, recon/dose AI, PCCT oncology).
  • Control hardware attach-rate and scanner-level bundling.

RT & Oncology Planning Vendors

  • Autocontour, Plan QA, Adaptive RT, response-linked planning, dose accumulation.
  • Value realized at per-room level with tight TPS/linac integration.

AI Platforms & Cloud Providers

  • Neutral marketplaces, orchestration layers, governed AIops platforms delivering one-contract deployment and monitoring.

Providers & Teleradiology Networks

  • AI-assisted screening, oncology reads, tumor-board support, and network QA; convert app level value into service line revenue and outcomes.

Imaging Pharma / CRO & Trials Players

  • Radiomics and quantitative endpoints, theranostics quant, lesion-level response analytics, RWE and HTA support.

Within each cluster, the report provides:

  • Markintel M3 (Market Momentum Matrix) - showing segments in four quadrants
  • GTM Growth-Maturity Matrices - showing market position of companies by cluster.
  • Competitive Datasets & Scoreboards - vendor roles, channels, evidence posture, regions of strength.

This gives strategists a clear view of where to partner, where to compete, and where to buy or build.

Why This Report

1. Built for strategy, not just market sizing

Most AI market reports stop at "how big is the TAM." This report is designed for board, C suite, and BU level decisions in oncology imaging AI. It links numbers directly to:

  • Portfolio choices (which modalities, tumor sites, and pathway stages to prioritize)
  • Platform and partnership strategy (OEMs, RT, platforms, providers, pharma)
  • Pricing, packaging, and upgrade ladders aligned to evidence and readiness

2. Explicitly pathway and attach rate driven

Oncology imaging AI uplifts do not come from scanner unit growth-they come from attach rate expansion and pathway adoption (screening, RT, theranostics, response monitoring). The model explicitly reconstructs revenue via:

  • Installed base and exam volumes by modality and country
  • Factory and retrofit attach-rates for oncology AI modules
  • ASP/ARPU bands by revenue stream and end use

This makes the forecasts more useful for OEMs, software vendors, and platforms that live in attach rate math-not just high level CIO dashboards.

3. Actionable frameworks for GTM and packaging

The Markintel framework stack turns data into concrete, testable plays:

  • M3 Market Momentum Matrix
  • ARC-Index tells you which use cases are deployment-ready vs pilot stage.
  • GTM Growth-Maturity matrices identify partners, M&A targets, and competitors by cluster.
  • Upgrade & Package Ladders show how to package oncology AI into Foundation / Advanced / Elite offerings with embedded commercial rules.

This is particularly valuable for:

  • Product & portfolio leaders - deciding where to invest, sunset, or bundle.
  • GTM, commercial, and pricing teams - defining SKUs, floors, and discount structures.
  • Investors and BD/M&A - identifying platforms and clusters with structural momentum.

4. Evidence-weighted and vendor agnostic

The analysis is evidence-weighted, not hype-led, and spans both incumbents and challengers across regions. It provides:

  • Neutral, structured coverage of leading and emerging vendors in each cluster.
  • Clearly labeled Evidence Confidence levels for placements and ARC scores.
  • A methodology that can be revisited and extended as new data, trials, and approvals come online.

5. Designed to be reused

Tables, charts, and frameworks are crafted so they can be dropped directly into internal decks, investment committees, BD memos, and board packs with minimal rework, helping teams:

  • Explain complex oncology AI dynamics to non technical stakeholders.
  • Justify budgets and strategic bets with quantified, segmented evidence.
  • Align product, sales, and partnership roadmaps around the same view of the market.

Companies Mentioned:

  • 5C Network
  • Accuray
  • Aidoc
  • AIQ Solutions
  • Bracco
  • Brainlab
  • Canon Medical
  • CARPL.ai
  • deepc (deepcOS)
  • DocPanel
  • Elekta
  • Everlight Radiology
  • Ferrum Health
  • Fujifilm Healthcare
  • GE HealthCare
  • Guerbet
  • Hologic
  • Incepto
  • Koios Medical
  • Lantheus / EXINI (aPROMISE / PYLARIFY AI)
  • Limbus AI
  • Lunit
  • Median Technologies
  • MIM Software
  • Mirada Medical
  • MVision AI
  • Nuance Precision Imaging Network (PIN)
  • Philips Healthcare
  • Quibim
  • QView Medical
  • RadNet / DeepHealth
  • RaySearch Laboratories
  • Riverain Technologies
  • Samsung Healthcare
  • ScreenPoint Medical (Transpara)
  • Siemens Healthineers
  • Teleradiology Solutions
  • Tempus (Arterys)
  • Therapixel (MammoScreen)
  • Unilabs / Telemedicine Clinic (TMC)
  • United Imaging
  • Vara
  • vRad

The list is cluster balanced-it includes AI software specialists, modality OEMs, RT/TPS vendors, platform players, provider/telerad networks, and imaging pharma/iCROs that feature in the oncology analysis.

TABLE OF CONTENTS

SECTION 1 - HOW TO USE THIS STRATEGY PULSE

  • What This Pulse Answers
  • How This Strategy Pulse Relates to The Horizon Research Program
  • Who Should Use This Pulse-And for What
  • What Is Not in Scope
  • How To Read the Rest of the Document

SECTION 2 - EXECUTIVE SUMMARY

  • Why This Market Matters - The 25-Second Read
  • Global Growth at A Glance (2023-2032)
  • Where Along the Pathway the Money Is Moving
  • Global Market Drivers & Restraints
    • Key Growth Drivers
    • Structural Restraints
  • Regional Pulse - Who Leads, Who Accelerates
    • North America
    • Asia-Pacific
    • Europe
    • LATAM & MEA
  • Evidence & Policy Signals to Watch (2025-2027)
  • Five Strategy Headlines to Internalize
  • Structural Shifts by Modality, Application, Pathway, And End-Use
  • Competitive Architecture and Vendor Clusters
  • Three-Year KPI Outlook (2025-2027) & Board-Level Actions
    • Three-Year KPI Outlook
    • Actions For Vendors Over the Next 12 Months

SECTION 3 - RESEARCH METHODOLOGY

  • About This Strategy Pulse
  • Scope & Segmentation
  • Evidence & Forecast Architecture - Dual-Lens Build
  • Framework Stack & Vendor Clustering
  • Evidence Confidence, Limitations & Interpretation

SECTION 4 - STRATEGIC ANALYSIS & FRAMEWORKS

  • CROSS-CLUSTER STRATEGY PLAYBOOKS (2025-2027)
  • AI SOFTWARE CLUSTER
    • Executive Summary
    • Markintel M3 - Market Momentum Matrix (AI Software Key Sub-Segments)
      • How to Read This Matrix
    • Markintel ARC Framework - Oncology Use Cases Addressable by AI Software Lens
      • Markintel ARC Grid - AI Software (Oncology Imaging AI)
      • How to Read This Exhibit
      • ARC-Index by Segment - AI Software (Oncology Imaging AI)
      • ARC -> Upgrade Ladder Mapping - AI Software
      • Recommendations (AI Software Vendors)
    • Markintel GTM Growth-Maturity Matrix - AI Software Vendors (Oncology Imaging AI)
      • How To Read This Matrix
      • Competitive Dataset - AI Software - Oncology Imaging AI
      • Company Scoreboard - AI Software - Oncology Imaging AI
      • AI Software - Market Segmentation Bridge
    • Markintel Upgrade & Package Ladder - AI Software (Oncology Imaging AI)
      • Objective
      • Upgrade Ladder Structure - AI Software (Oncology) Packages
      • Target Customers & Package Composition - AI Software - Oncology Upgrade & Package Ladder42 Recommended Commercial Rules - AI Software (Oncology)
    • Company Spotlights - AI Software Cluster
      • Aidoc
      • AIQ Solutions
      • Koios Medical
      • Lunit
      • Median Technologies
      • Quibim
      • QView Medical
      • RadNet / DeepHealth
      • Riverain Technologies
      • ScreenPoint Medical (Transpara)
      • Therapixel (MammoScreen)
      • Vara
    • IMAGING OEMs CLUSTER (ONCOLOGY ATTACH & AI SUITES)
      • Executive Summary
      • Markintel M3 - Market Momentum Matrix (Imaging OEMs Key Sub-Segments)
        • How to Read This Matrix
      • Markintel ARC Framework - Oncology Imaging AI Use Cases Addressable by OEMs
        • Key OEM Oncology Segments
        • ARC Grid - Imaging OEMs
        • How to Read This Exhibit
        • ARC Table - Imaging OEMs (Oncology)
      • Markintel GTM Growth-Maturity Matrix - Imaging OEMs (Oncology Imaging AI)
        • Competitive Dataset - Imaging OEMS - Oncology Imaging AI
        • How to Read this Matrix
        • Imaging OEMs Competitive Scoreboard - Oncology Imaging AI
        • Imaging OEMs Cluster - Oncology Imaging AI Market Segmentation Bridge
      • Upgrade & Package Ladder - Imaging OEMs Lens (Oncology Imaging AI)
        • Objective
        • Ladder Structure - OEM Oncology Packages
        • Imaging OEMs - Oncology AI Upgrade & Package Ladder - Target Customers & Package Composition
        • Recommended Commercial Rules - OEM Oncology Cluster
      • Company Spotlights - Imaging OEMs (Oncology Attach & AI Suites)
        • Canon Medical
        • Fujifilm Healthcare
        • GE HealthCare
        • Hologic
        • Philips Healthcare
        • Samsung Healthcare
        • Siemens Healthineers
        • United Imaging
    • RT / ONCOLOGY PLANNING CLUSTER (AUTO-CONTOUR, ADAPTIVE, DOSE/RESPONSE)
      • Executive Summary
      • Markintel M3 - Market Momentum Matrix of Key Subsegments (RT/Oncology Planning Lens)
        • What it Says (RT / Oncology Planning)
      • Markintel ARC-Framework by Oncology Use Case (RT/Oncology Planning Lens)
        • ARC Grid - RT/Oncology Planning
        • ARC Table - RT / Oncology Planning
        • RT Recommendations
      • Markintel GTM Growth-Maturity Matrix -- RT & Oncology Planning Vendors (Oncology Imaging AI)
        • Competitor Scoreboard
        • RT / Oncology Planning - Market Segmentation Bridge
      • Markintel Upgrade & Package Ladder - RT / Oncology Planning
        • Objective
        • Ladder structure - RT / Oncology Planning packages
        • RT/Oncology Planning Cluster - Oncology AI Upgrade & Package Ladder - Target Customers & Package Composition
        • Recommended Commercial Rules - RT / Oncology Planning
      • Company Spotlights - RT / Oncology Planning
        • Accuray
        • Brainlab
        • Elekta
        • Limbus AI
        • MIM Software
        • Mirada Medical
        • MVision AI
        • RaySearch Laboratories
        • Varian (Siemens)
    • AI PLATFORMS & CLOUD CLUSTER (NEUTRAL PLATFORMS, ORCHESTRATION, MARKETPLACES)
      • Executive Summary
      • Markintel M3 - Market Momentum Matrix (AI Platforms & Cloud Key Sub-Segments)
        • What it Says (AI Platforms & Cloud)
      • Markintel ARC Framework - Oncology Use Cases Addressable by AI Platforms & Cloud
        • ARC Grid - AI Platforms & Cloud
        • ARC Table - AI Platforms & Cloud
        • Markintel GTM Growth-Maturity Matrix - AI Platforms & Cloud Providers (Oncology Imaging AI)74 Competitor Scoreboard
        • AI Platforms & Cloud - Market Segmentation Bridge
      • Upgrade & Package Ladder - AI Platforms & Cloud (Oncology)
        • Objective
        • Ladder Structure - Platform & Cloud packages
        • AI Platforms & Cloud - Oncology Upgrade & Package Ladder - Oncology Imaging AI
        • Recommended Default commercial Rules - Platforms & Cloud
      • Company Spotlights - AI Platforms & Cloud
        • CARPL.ai
        • deepc (deepcOS)
        • Ferrum Health
        • Incepto
        • Nuance Precision Imaging Network (PIN)
        • Tempus (Arterys)
    • PROVIDERS & TELERADIOLOGY CLUSTER (AI-ASSISTED SERVICES)
      • Executive Summary
      • Markintel M3 - Market Momentum Matrix (Providers & Teleradiology Key Subsegments)
        • What it Says (Providers & Telerad)
      • Markintel ARC Framework - Oncology Use Cases Addressable by Providers & Teleradiology
        • ARC Grid - Providers & Teleradiology
        • ARC Table - Providers & Teleradiology
      • GTM Growth-Maturity Matrix - Providers & Teleradiology Networks (Oncology Imaging AI)
        • Competitive Dataset - Services Rails, Governance, Oncology Footprint
        • Competitive Scoreboard
        • Providers & Teleradiology - Market Segmentation Bridge
      • Markintel Upgrade & Package Ladder - Providers & Teleradiology (Oncology)
        • Objective
        • Ladder Structure - Oncology Service Packages
        • Providers & Teleradiology - Oncology Upgrade & Package Ladder - Target Customers & Package Composition
        • Recommended Default Commercial Rules - Providers & Teleradiology
      • Company Spotlights - Providers & Teleradiology (AI-Assisted Services)
        • 5C Network
        • Everlight Radiology
        • DocPanel
        • RadNet / DeepHealth
        • Teleradiology Solutions
        • Unilabs / Telemedicine Clinic (TMC)
        • vRad
    • IMAGING-PHARMA / CRO & TRIALS CLUSTER (RADIOMICS, RESPONSE, THERANOSTICS)
      • Executive Summary
      • Markintel M3 - Market Momentum Matrix (Imaging-Pharma / CRO & Trials Key Sub-Segments)
        • M3 Table - Imaging-Pharma / CRO & Trials
      • Markintel ARC Framework - Oncology Imaging AI Use Cases Addressable by Imaging-Pharma / CRO & Trials
        • ARC Grid - Imaging-Pharma / CRO & Trials
        • ARC Table - Imaging-Pharma / CRO & Trials
      • Markintel GTM Growth-Maturity Matrix - Imaging-Pharma & CROs (Oncology Imaging AI)
        • Competitive Dataset - endpoint standardization & clinic bridge
        • Competitor Scoreboard
        • Imaging-Pharma / CRO & Trials - Market Segmentation Bridge
      • Upgrade & Package Ladder - Imaging-Pharma / CRO & Trials
        • Objective
        • Ladder Structure - Imaging-Pharma / CRO & Trials
        • Imaging-Pharma / CRO & Trials - Upgrade & Package Ladder - Target Customers and Package Composition
        • Recommended Default Commercial Rules - Imaging-Pharma / CRO & Trials
      • Company Spotlights - Imaging-Pharma / CRO & Trials (Radiomics, Response, Theranostics)
        • AIQ Solutions
        • Bracco
        • Guerbet
        • Lantheus / EXINI (aPROMISE / PYLARIFY AI)
        • Median Technologies
        • Quibim

List of Figures

  • Figure 1: World Oncology Imaging AI Market by Pathway Stage - 2023 vs 2032
  • Figure 2: Oncology Imaging AI - Global Drivers & Restraints
  • Figure 3: Oncology Imaging AI Market by Region - 2032 Revenue and 2023-2032 CAGR
  • Figure 4: Oncology Imaging AI Market by Modality - 2023 vs 2032
  • Figure 5: Oncology Imaging AI Market by Clinical Application - 2023 vs 2032
  • Figure 6: Oncology Imaging AI - Competitive Cluster Architecture
  • Figure 7: Markintel M3 - Market Momentum Matrix (AI Software Key Sub-Segments)
  • Figure 8: Markintel ARC Grid - AI Software - Oncology Imaging AI
  • Figure 9: Markintel GTM Growth vs. Maturity Matrix - AI Software Vendors (Oncology Imaging AI)
  • Figure 10: Upgrade & Package Ladder - AI Software - Oncology Imaging AI
  • Figure 11: Markintel M3 - Market Momentum Matrix (Imaging OEMs)
  • Figure 12: Markintel ARC Grid - Imaging OEMs - Oncology Imaging AI
  • Figure 13: Markintel GTM Growth vs. Maturity Matrix - Imaging OEM Vendors (Oncology Imaging AI)
  • Figure 14: Upgrade & Package Ladder - Imaging OEM Cluster - Oncology Imaging AI
  • Figure 15: Markintel M3 - Market Momentum Matrix - RT/Oncology Planning (Oncology Imaging AI) .
  • Figure 16: Markintel ARC Grid - RT/Oncology Planning - Oncology Imaging AI
  • Figure 17: Markintel GTM Growth vs. Maturity Matrix - RT/Oncology Planning (Oncology Imaging AI)
  • Figure 18: Upgrade & Package Ladder - RT/Oncology Planning Cluster - Oncology Imaging AI
  • Figure 19: Markintel M3 - Market Momentum Matrix (AI Platform & Cloud Sub-segment)
  • Figure 20: Markintel ARC Grid - AI Platforms & Cloud - Oncology Imaging AI
  • Figure 21: Markintel GTM Growth vs. Maturity Matrix - AI Platforms and Cloud (Oncology Imaging AI)
  • Figure 22: Upgrade & Package Ladder - AI Platforms & Cloud - Oncology Imaging AI
  • Figure 23: Markintel M3 - Market Momentum Matrix (AI Providers & Teleradiology Sub-Segment)
  • Figure 24: Markintel ARC Grid - Providers & Teleradiology - Oncology Imaging AI
  • Figure 25: Markintel GTM Growth vs. Maturity Matrix - Providers & Teleradiology (Oncology Imaging AI)
  • Figure 26: Upgrade & Package Ladder - Providers & Teleradiology Cluster - Oncology Imaging AI
  • Figure 27: Markintel M3 - Market Momentum Matrix (Imaging-Pharma/CRO & Trials Key Sub-Segment)
  • Figure 28: Markintel ARC Grid - Imaging-Pharma / CRO & Trials - Oncology Imaging AI
  • Figure 29: Markintel GTM Growth vs. Maturity Matrix - Imaging-Pharma / CRO & Trials (Oncology Imaging AI)
  • Figure 30: Upgrade & Package Ladder - Imaging-Pharma / CRO & Trials - Oncology Imaging AI